Detailed Narrative
Sustainability Recognition: EcoVadis Gold Medal
Hikal Limited was recently awarded the EcoVadis Gold Medal Rating, achieving an overall score of 84 on 100 and a 97 percentile ranking. This places the company among the top 5% of over 175,000 companies globally assessed for sustainable performance. This recognition validates Hikal's focus on sustainability, operational excellence, compliance, and governance, reinforcing customer, partner, and investor confidence.
Q1 FY27 Financial Performance Overview
For Q1 FY27, Hikal reported a revenue of ₹403 crores with an EBITDA margin of 9.2%, and a PAT of ₹(-7) crores. The quarter marked a transition from regulatory-led disruption to execution-led growth, supported by improving customer ordering patterns and product mix. The company continued to strengthen its Pharmaceutical, Crop Protection, and Animal Health businesses while entering the new Personal Care division.
Pharmaceutical Business Performance and FDA Remediation
The Pharmaceutical business delivered ₹233 crores in revenue with an EBIT of ₹8 crores (3.2% margin), showing year-on-year growth despite a planned shutdown for U.S. FDA remediation efforts. Customer ordering patterns are normalizing, and the remediation program is on track, with re-inspection expected towards the end of FY27. The company's new pilot plant in Panoli is operational, aiming to increase DMF filings from 2-3 to 6-7 per year, and no customer contracts have been lost in the past 12 months.
Crop Protection Business Challenges and Strategy
The Crop Protection business reported ₹170 crores in revenue with an EBIT of ₹(-6) crores. The segment faced margin pressure due to elevated raw material and fuel costs from geopolitical tensions, and continued pricing pressure from China's excess supply. Global channel inventories have largely normalized, but customer ordering remains need-based. Hikal's strategy focuses on securing contracts, cost discipline, and selective investments in de-bottlenecking and new capacities backed by long-term contracts, expecting gradual volume recovery.
Growth Drivers: Animal Health and Personal Care
The Animal Health business delivered another strong quarter, driven by robust demand and approval of validation qualities for new projects, with a target of ₹400 crores plus in revenue by FY30 and EBITDA margins over 20%. The newly commissioned Personal Care segment, with a dedicated manufacturing line at Panoli, is expected to generate revenue by the end of this year and aims for ₹200 crores in revenue within the next three years with EBITDA margins over 20%.
Capital Allocation and Debt Management
Hikal invested ₹45 crores in capital expenditure during Q1 FY27, focused on de-bottlenecking, regulatory upgrades, and new capacities. Over the last four years, the company invested ₹900 crores in CAPEX, with ₹300 crores for maintenance and ₹600 crores for growth initiatives including an agrochemical plant (now retooled), an Animal Health site, and a multipurpose facility. Net debt has been reduced from ₹815 crores in FY24 to ₹685 crores by FY26, bringing the debt-to-equity ratio to 0.53.
Outlook and Future Growth Strategy
Hikal expects positive momentum to continue, with substantial growth in revenues and EBITDA from Q2 onwards, accelerating in H2 FY27. Full-year FY27 growth is projected at 14%-16% for revenue and 25%-30% for EBITDA. The company anticipates a 15%-16% CAGR beyond FY27, with Pharma growing at 18%-19%. The long-term strategy involves diversifying into four divisions (Pharma, Animal Health, Personal Care, and Crop Protection) with Pharma and allied businesses contributing 70%-80% of total revenue.